Heidi Ko
@CancerDocKo
Director of Medical Affairs @Labcorp Oncology. Breast Medical Oncologist. Former Hem/Onc Fellow @MontefioreNYC. Former resident @UTHimres. Alum @UNC. #BCSM
You might like
Thank you @JNCCN 🙌🏼 #MedTwitter #bcsm #nccn #breastcancer
Clinical Utility of 18F-FDG PET/CT in Staging Localized #BreastCancer Before Initiating Preoperative Systemic Therapy: buff.ly/3i4q5Lk #BCSM #radonc @CancerDocKo @CharitoLoveMD1 @jsparano
We all will be having this conversation and cross trial comparison for every EGFR mNSCLC pt we see in the clinic. Take a minute to get a real pt perspective by @jillfeldman4 👇👇 #FLAURA2 & #MARIPOSA data! #WCLC25 #OncTwitter #lcsm
The new FLAURA2 OS data presented at #WCLC25 is exciting - nearly four years of median OS with osimertinib + chemotherapy is remarkable progress for our community! Alongside the MARIPOSA data, it's essential to remember -- this isn't about competition. There is no…
Excited to Share @Labcorp's Oncology Testing Solutions at @ASCO 2025 - Heidi Ko (@CancerDocKo) oncodaily.com/blog/heidi-ko-… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ASCO2025 #Labcorp @CancerWorldmag
There’s no Level 1 evidence that our current frequency of post-treatment surveillance imaging & labs reduces the risk of death. (From NEJM piece on pros/cons of routine surveillance protocols, especially relevant in current ctDNA era) – worth a read! nejm.org/doi/full/10.10…
Online now for the #AACR25 session on Advances in #KRAS Biology in PDAC by session speaker @andrewaguirremd: Response and Resistance to RAS inhibition in Cancer brnw.ch/21wSgTw
Evolution of HER2 testing over 40 yrs. IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging. We presented data with HS-HER2 to predict T-DXd activity at #ESMO24. More data coming at #ASCO25. Stay tuned. nature.com/articles/s4157…
PSA to cancer patients out there. Putting the word integrative in front of their name does not make a non-oncologist an oncologist. Cancer biology is incredibly complicated and takes decades to learn. If someone did not do medical oncology fellowship they are not med onc. #bcsm
HER2 is no longer just a breast/Upper GI cancer story. ADCs are changing the landscape, making HER2 a tissue-agnostic target across multiple tumor types. Our mini-review article in @FrontOncology on the subject. @OncoAlert frontiersin.org/journals/oncol…
ctDNA in CRC is prognostic, but there is no data showing that treatment initiated earlier based upon ctDNA positivity confers improved survival (or QOL). Earlier detection alone does not equal benefit. Great job @KristenCiombor 👏👏 #GI25
2024 approvals: Summary of 6 new drugs/indications in GI Malignancies by @US_FDA 1. #LiposomalIrinotecan 2. #Adagrasib 3. #Zolbetuximab 4. #Zanidatamab 5. #Zenocutuzumab 6. #Encorafenib #gism #OncTwitter #MedTwitter #PancChat
Summary of 5 new drugs/indications in GI malignancies that were @FDAOncology @US_FDA approved in 2023: - #Tucatinib - Mountaineer - #TAS102 + #Bevacizumab - Sunlight - #Pembro + Cis/Gem - KN966 - #Fruquintinib - FRESCO2 - #Pembro + Chemo - KN859 #OncTwitter #gism #crcsm
I’m so honored to present this important study on patient awareness of HER2-low breast cancer, led by amazing @BeccaPrevisMD @Labcorp @outcomes4me at #SABCS24 🌟 ➡️ Patient awareness gaps exist and education increases biomarker awareness and empowers pt-doc discussion
As I try to figure out INAVO120, I would like to point out that patients with PIK3CA mutations do very well on first line Abema/Fulv or Ribo/Fulv with median PFS beyond 16 months in registrational trials. Palbo/Fulv as a control arm is questionable Thanks @Larvol for dataset.
Node-negative subanalysis of NATALEE (n=613). Mostly includes patients with T2 disease (75%), virtually all with G2-3 disease. Consistent benefit in iDFS (93.2% vs 90.6%, HR 0.72), DDFS and DRFS with adjuvant ribociclib. Safety also consistent with ITT. #ASCO24 #bcsm
1. 1998: the FDA approves trastuzumab. HER2+ becomes clinically relevant. 2. 2022: T-DXd improves outcomes in HER2-low MBC. HER2-low becomes clinically relevant. 3. 2024: T-DXd improves outcomes in HER2-low + ultralow. HER2-ultralow becomes clinically relevant. 4. Stay tuned
In 2020 we proposed to add a #HER2Low slice to the HER2 pie chart, an addition that has now entered practice. But further changes await us in the coming years. Excited to share our latest Cancer Discovery piece, outlining the present & future of HER2-low! aacrjournals.org/cancerdiscover…
The OncoAlert🚨NEWSLETTER OUT Covering May 2-8, 2024 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… ✅ @TheLancet Commission on #ProstateCancer ✅DESTINY-PanTumor01 ✅Osimertinib+Local tx for brain🧠mets in EGFRm #NSCLC 🫁 ✅ASCENT in Triple Negative…
A lot of buzz with ADCs in oncology. The journey has not been easy. There’re only 5 approved ADCs in solid tumors in last 10 years. Here’s my summary…@OncoAlert #AACR #ASCO
⭐️Just published in time for the #ELCC24 👉The Impact of Prior Single-Gene Testing(SGT) on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer 👉For patients with NSCLC, initial use of SGT increases subsequent CGP test cancellations, turnaround…
We are profoundly grateful that Dr. Ruth Gottesman, Professor Emerita of Pediatrics at @EinsteinMed, has made a transformational gift to #MontefioreEinstein—the largest to any medical school in the country—that ensures no student has to pay tuition again. bit.ly/3wvBj7y
Big shoutout to the organizing committee of #SABCS23 🙌 Thank you for actively listening to the ILC community's voice and incorporating a dedicated ILC session this year. Your responsiveness is a testament to the commitment to inclusivity and collaboration in advancing breast…
United States Trends
- 1. Black Friday 310K posts
- 2. #releafcannabis N/A
- 3. Good Friday 50.3K posts
- 4. #FanCashDropPromotion N/A
- 5. #DaesangForJin 55K posts
- 6. #AVenezuelaNoLaTocaNadie 1,011 posts
- 7. #ENHYPEN 202K posts
- 8. ARMY Protect The 8thDaesang 58.4K posts
- 9. Third World Countries 42.1K posts
- 10. Victory Friday N/A
- 11. yeonjun 67.1K posts
- 12. Mnet 209K posts
- 13. Sarah Beckstrom 263K posts
- 14. Cyber Monday 5,223 posts
- 15. Lamar 48.9K posts
- 16. TODAY ONLY 63.2K posts
- 17. Stormzy 2,020 posts
- 18. Mr. President 20.6K posts
- 19. Wegmans 2,377 posts
- 20. BNB Chain 6,768 posts
You might like
-
Urvi Shah
@UrviShahMD -
Astha Thakkar
@asthakkar15 -
Ayushi Chauhan
@Chauhan_AF -
Ivy Riano, M.D.
@IvyLorena_Md -
Carolina Bernabe
@BernabeCarolina -
Elaine Shum
@ElaineShumMD -
Marcela Mazo MD
@mazo_md -
Murali Janakiram
@JanakiramMurali -
Mariam Alexander
@MariamAlex26 -
Dawood Findakly, MD, FACP
@dawood_findakly -
Richa Parikh
@richaparikh36 -
Maria Antonia Vélez
@MomaVelez11 -
Mabel Mardones, MD
@mabelonc -
Amit Verma
@Amitvermamds -
Missak Haigentz
@DrHaigentz
Something went wrong.
Something went wrong.